NASDAQ:MGRX Mangoceuticals Q1 2025 Earnings Results & Report $0.34 -0.03 (-7.70%) As of 01:49 PM Eastern This is a fair market value price provided by Massive. Learn more. Mangoceuticals reported Q1 2025 earnings on May 15, 2025. The company reported EPS of -$1.29, while revenue was $0.11 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 15, 2025TimeAfter Market ClosesConference Call12:00 AM ET Mangoceuticals EPS ResultsActual EPS-$1.29Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMangoceuticals Revenue ResultsActual Revenue$0.11 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Mangoceuticals Q1 2025 Earnings FAQ Did Mangoceuticals beat earnings estimates for Q1 2025? Mangoceuticals (NASDAQ:MGRX) reported earnings of -$1.29 per share for Q1 2025. The report was announced on Thursday, May 15, 2025. What was Mangoceuticals' revenue for Q1 2025? Mangoceuticals reported revenue of $0.11 million for Q1 2025. Mangoceuticals Earnings HeadlinesMangoceuticals (NASDAQ: MGRX) closes 74% premium stock sale with warrantsOctober 12 at 5:34 AM | americanbankingnews.comMangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market CloseOctober 9, 2026 | finance.yahoo.comWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run, and Vertiv before a 1900 percent run. Now he's tracking a radical light-speed technology that could make AI 100 times faster and 100 times more energy efficient. Stocks tied to it have already climbed 133 percent, 217 percent, and 320 percent.October 14 at 1:00 AM | Brownstone Research (Ad)Mangoceuticals completes premium registered direct equity financingOctober 9, 2026 | tipranks.comMangoceuticals Secures $2.5 Mln Investment To Advance Antiviral IP CommercializationOctober 2, 2026 | rttnews.comMangoceuticals, Inc.: Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million TrancheOctober 2, 2026 | finanznachrichten.deSee More Mangoceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mangoceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mangoceuticals and other key companies, straight to your email. Email Address About MangoceuticalsMangoceuticals (NASDAQ:MGRX) is a telehealth and men’s wellness company that provides online access to treatments and products focused primarily on sexual health, hair care and related wellness needs. The company markets its services directly to consumers through its digital platform, where customers can complete an online health assessment and, when appropriate, receive a prescription from a licensed medical provider. Its product offerings have included MangoRx, a branded oral treatment for erectile dysfunction formulated with prescription ingredients such as tadalafil and sildenafil, as well as products and programs addressing hair loss and testosterone-related concerns. Mangoceuticals also offers nonprescription wellness products and personalized treatment options intended to support men’s health. The company primarily serves customers in the United States through its online platform and relies on third-party pharmacies and healthcare providers to support prescription fulfillment and clinical services. Its Nasdaq-listed securities trade under the symbol MGRX. Treatment availability may vary by state and is subject to applicable medical and regulatory requirements.View Mangoceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenPBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough Road Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
